N-SUBSTITUTED HETEROCYCLIC DERIVATIVES OR THEIR SALTS, INTERMEDIATE DERIVATIVES OF PYRIMIDINE AND IMIDAZOLINE AND A PHARMACEUTICAL COMPOSITION BASED ON THE SUBSTITUTED HETEROCYCLIC DERIVATIVES Russian patent published in 1997 - IPC

FIELD: organic chemistry. SUBSTANCE: product: N-substituted heterocyclic derivatives of the formula (I) given in description where R₁ and R₂ are similar or different and each means independently hydrogen or group taken among C₁-C₄-alkyl, cyano, tetrazolyl, methyltetrazolyl, methylsulfonylamino, trifluoromethylsulfonylamino, trifluoromethylsulfonylaminomethyl, N-cyanoacetamide, N-hydroxyacetamide, N-[(4-carboxy)-1,3-thiazole-2-yl]-acetamide, ureido, 2-cyanoguanidinecarbonyl, 2-cyanoguanidinemethyl, 1-imidazolylcarbonyl, 3-cyano-2-methylisothioureidomethyl at condition that at least one of substituents R₁ and R₂ is distinct from hydrogen; R₃ means hydrogen, (C₁-C₆)-alkyl that can be free or substituted with one or some halogen atoms, (C₂-C₆)-alkenyl, (C₃-C₇)-cycloalkyl, phenyl, (C₁-C₃)-phenylalkyl; R₄ and R₅ each means independently (C₁-C₆)-alkyl, phenyl being alkyl and phenyl were not substituted or substituted with one or some halogen atoms or a single group of (C₁-C₄)-perfluoroalkyl; R₄ and R₅ together form group of the formula CR₇R₈ where R₇ means hydrogen and R₈ - phenyl; or R₄R₅ combined together mean group of the formula (CH₂)_n where n = 3-11; if this group is cyclohexane it can be substituted with (C₁-C₄)-alkyl or phenyl; or group (CH₂)_pY(CH₂)_q where p = q = 2; -y - HR₆; R₆ - acetyl, COF₃,COC₆H₅, residue of Arg, Asp, Cys or Ile; or R₄ and R₅ combined together with carbon atom to which they bound form indan or adamantane; X means oxygen or sulfur atom; Z and t = 0 or one of their = 0 and another = 1; or their salts and intermediate compounds - derivatives of pyrimidine and imidazoline and pharmaceutical composition containing compound (I) as an active component at effective amount. The synthesized compounds show antagonistic effect with respect to angiotensin-II and can be used in medicine for treatment of cardiovascular illnesses. EFFECT: improved method of synthesis. 11 cl